PurpleDaisy Logo
PurpleDaisyResources
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog
Download on the App Store
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog

Biomarker Encyclopedia

500+ Items
Master Catalogs
  • All 500+ Biomarkers Directory
  • Longevity Reference MatrixPDF
Categories (500+ Markers)
  • Cardiovascular & Lipidology
  • Metabolic & Glycemic Control
  • Renal Physiology & Electrolytes
  • Hepatic & Biliary Function
  • Hematology & CBC
  • Iron Metabolism & Oxygen Transport
  • Endocrinology & Hormones
  • Micronutrients & Vitamins
  • Immunology & Longevity Clocks
Download Meridian on the App Store
Home/Biomarkers/Hepatic & Biliary Function/ALT
Hepatic & Biliary FunctionHepatocellular Integrity & Amino Acid Transamination

Alanine Aminotransferase (ALT)

Alanine aminotransferase is a cytosolic transaminase enzyme localized primarily within hepatocytes. It is the most specific circulating biomarker for acute or chronic hepatocellular injury.

Standard Range7 - 56 U/L (Commercial lab ceiling often up to 50 U/L)
Optimal Longevity12 - 25 U/L (Male: < 30 U/L, Female: < 20 U/L)
Measurement UnitU/L
Organ SystemHepatocellular Integrity & Amino Acid Transamination
Routine Panels:Comprehensive Metabolic Panel (CMP)Hepatic Function Panel

Standard vs. Optimal Reference RangesU/L

Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.

Interactive Range Analyzer
Unit: U/L
U/L
Presets:
4 U/LOptimal Zone Target76 U/L
Optimal Longevity Zone(18.5 U/L)

Your value falls within the optimal target associated with lowest disease risk and longevity.

Standard Reference Interval

7 - 56 U/L (Commercial lab ceiling often up to 50 U/L)

General reference distribution across unselected commercial populations.

Optimal Longevity Target

12 - 25 U/L (Male: < 30 U/L, Female: < 20 U/L)

Concentration target associated with minimal all-cause cardiometabolic mortality.

Molecular Mechanism & Clinical Purpose

ALT catalyzes the reversible transfer of an amino group from L-alanine to alpha-ketoglutarate, producing pyruvate and L-glutamate for the tricarboxylic acid (TCA) cycle. Hepatocyte plasma membrane damage releases cytosolic ALT into the systemic circulation.

Differential Diagnosis

Elevated Levels (ALT High)

  • •Metabolic dysfunction-associated steatohepatitis (MASH / NAFLD)
  • •Viral hepatitis (A, B, C)
  • •Alcohol-related liver disease
  • •Drug-induced liver injury (Acetaminophen, statins, NSAIDs)

Low Levels (ALT Low)

  • •Optimal hepatic parenchymal integrity
  • •Vitamin B6 (Pyridoxal-5-phosphate) deficiency (co-factor for ALT assay)

Technical Reference & Deep Dive

Biochemistry & Enzymatic Pathways
Alanine Aminotransferase (ALT) reflects hepatocyte integrity, biliary canalicular transport, and hepatic synthetic capacity. Hepatic parenchymal cells synthesize proteins, metabolize xenobiotics via cytochrome P450 monooxygenases, and conjugate endogenous substrates via UDP-glucuronosyltransferases. Cellular membrane disruption from lipid peroxidation, bile acid toxicity, or immune-mediated cytolysis releases intracellular enzymes into systemic circulation. Synthesis rates of carrier proteins depend directly on ribosomal transcription and functional hepatic mass.
Longevity Risk Architecture & Epidemiology
Conventional laboratory cutoffs (up to 55 U/L) were calibrated on populations with undetected fatty liver. True healthy reference populations demonstrate normal ALT ceilings of 30 U/L for men and 20 U/L for women.
Pre-Analytical Caveats & Diagnostic Workup

Pre-Analytical Considerations:

A 12-hour overnight fast is recommended, especially if assessing biliary markers or lipid-associated hepatic enzymes. Complete abstinence from ethanol for at least 48 to 72 hours prior to testing is mandatory to prevent enzyme induction. Avoid strenuous unaccustomed weightlifting for 48 hours prior, which can release muscular transaminases and elevate AST/ALT.

Reflexive Testing Protocol:

  • Comprehensive Hepatic Viral Panel (Hepatitis A IgM, HBsAg, HBcAb, HCV antibody with reflex PCR)
  • Vibration-Controlled Transient Elastography (FibroScan) or Magnetic Resonance Elastography to quantify hepatic fat and fibrosis
  • Serum Ferritin and Total Iron-Binding Capacity (TIBC) to screen for hereditary hemochromatosis
  • Autoimmune Liver Disease Serology (Anti-Nuclear Antibodies, Anti-Smooth Muscle Antibodies, Anti-Mitochondrial Antibodies)
  • Abdominal Right Upper Quadrant Ultrasound to assess hepatic parenchyma, biliary ducts, and portal vein flow
Clinical Citations & Primary Literature (1)
  • [1]Re-evaluating Normal Alanine Aminotransferase Cutoffs in Clinical Practice - Hepatology (2021). PMID: 33894012
Common Panels:Comprehensive Metabolic Panel (CMP)Hepatic Function Panel
View All Panels

Associated Longevity Guides & Clinical Calculators

Medicine 3.0

Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Alanine Aminotransferase (ALT) into overall healthspan optimization.

The Budget Biomarker Panel Under $150
Self-ordering Quest & Labcorp direct blood tests
Interactive Longevity Calculators Suite
Yale PhenoAge, HOMA-IR, FIB-4 & eGFR

Related Hepatic & Biliary Function Biomarkers

Aspartate Aminotransferase
AST · 15 - 25 U/L
AST to ALT Ratio (De Ritis Ratio)
AST/ALT Ratio · 0.8 - 1.0 (with both enzymes in normal low range)
Gamma-Glutamyl Transferase
GGT · 10 - 20 U/L
Serum Albumin
Albumin · 4.5 - 5.0 g/dL
PreviousTotal Serum Calcium (Ca)Renal Physiology & ElectrolytesNextAspartate Aminotransferase (AST)Hepatic & Biliary Function